Sort
82,697 grants matching “vaccine development”
Features of Broad T Cell Coronavirus Immunity
$1,987,375Andrew D Luster · Brigham And Women'S Hospital · P01 · FY2023 · AI
NONHUMAN PRIMATE CORE HUMORAL IMMUNOLOGY LAB AIDS VACCINE R&D
$1,987,141David C Montefiori · Duke University · N01 · FY2017 · AI
Adjuvant Development within the context of a vaccine to protect against B. pertussis for use in newborns.
$1,986,305Ofer Levy · Boston Children'S Hospital · N01 · FY2022 · AI
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,985,712Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2016 · IP
HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)
$1,985,586Stephen A Spector · University Of California, San Diego · UM1 · FY2024 · AI
Viral Hemorrhagic Fevers: Disease Modeling and Transmission
$1,985,455Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Flavivirus Infections: Pathogenesis and Prevention
$1,985,380Alan L Rothman · University Of Rhode Island · P01 · FY2012 · AI
MALARIA VACCINE PRODUCTION &SUPPORT SERVICES
$1,985,074Science Applications International Corp · N01 · FY2000 · AI
Host-tumor cell interaction in myeloma: therapeutic applications
$1,984,614Kenneth C Anderson · Dana-Farber Cancer Inst · P01 · FY2011 · CA
Duke SPORE in Brain Cancer
$1,984,462John H Sampson · Duke University · P50 · FY2020 · CA
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
$1,984,196Ofer Levy · Boston Children'S Hospital · U19 · FY2019 · AI
IMPACTA PERU CLINICAL TRIALS UNIT
$1,984,088Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2016 · AI
Adjuvant Development in the context of vaccines for Zika, Dengue and West Nile virus
$1,983,970Sunil David · Virovax Llc · N01 · FY2022 · AI
Structure-Based Antagonism of HIV-1 Envelope Function in Cell Entry
$1,983,930Irwin M Chaiken · Drexel University · P01 · FY2018 · GM
Eliciting B cells to produce anti-HIV gp41 MPER-specific neutralizing antibodies
$1,983,517Ellis L Reinherz · Dana-Farber Cancer Inst · U19 · FY2012 · AI
Product Development and Manufacture
$1,982,812Robert T McNally · Geovax, Inc. · U19 · FY2009 · AI
Malaria Vaccine: AMA1-C2
$1,982,505Louis Miller · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
The Biology of HIV Infections
$1,982,083Malcolm Martin · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)
$1,981,971Hagop Kantarjian · University Of Tx Md Anderson Can Ctr · P01 · FY2009 · CA
Aging and Immunity to Infections
$1,981,756Trudeau Institute, Inc. · P01 · FY2005 · AG
Establishment and Expansion of SPF Rhesus Colony
$1,981,592Rudolf P Bohm · Tulane University Of Louisiana · U24 · FY2009 · RR
Clonal and imaging analyses of in vivo hematopoiesis, immune cell ontogeny and adoptive cell therapies
$1,981,553Cynthia E Dunbar · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL
CLINICAL AND LABORATORY STUDIES OF MALIGNANT LYMPHOMAS
$1,981,322Stanford University · P01 · FY2000 · CA
BREAD: A Modern Approach Towards Developing Vaccines for Critical Bovine Diseases Impacting Smallholder Farmers in Sub-Saharan Africa
$1,980,782John W Barlow · University Of Vermont & State Agricultural College · · FY2010 · BIO
Operations and Management
$1,980,753Dennis R. Burton · Scripps Research Institute, The · UM1 · FY2014 · AI